Sonoma Biotherapeutics
- Headquarters
- Seattle, Washington
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- sonomabio.com
- Total Funding
- $410.0M
- Last Round
- $75.0M Corporate RoundSep 2024
About
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company uses proprietary platform technologies to engineer targeted, durable Treg cell therapies. Its lead program targets rheumatoid arthritis, with additional indications in development through a collaboration with Regeneron.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account